Published online before print June 26, 2006, doi: 10.1161/CIRCULATIONAHA.106.630715
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;114:48-54.)
© 2006 American Heart Association, Inc.
Vascular Medicine |
Bosentan Therapy in Patients With Eisenmenger Syndrome
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study
From the Istituto di Cardiologia, Università di Bologna, Bologna, Italy (N.G.); Cardiology Unit, Hôpital des Enfants, Geneva, Switzerland (M.B.); Adult Congenital Heart Centre, Royal Brompton Hospital, and the National Heart and Lung Institute, Imperial College, London, UK (M.A.G.); Toronto General Hospital, Toronto, Ontario, Canada (J.G.); University Medical Center of Groningen, Groningen, the Netherlands (R.M.F.B.); Actelion Pharmaceuticals Ltd, Allschwil, Switzerland (A.L., E.C.); and Boston Adult Congenital Heart and Pulmonary Hypertension Group, Children’s Hospital, BWH and BIDMC, Boston, Mass (M.L.).
Reprint requests to Nazzareno Galiè, MD, Istituto di Cardiologia, Università di Bologna, Via Massarenti, 9 IT-40138, Bologna, Italy. E-mail nazzareno.galie{at}unibo.it
Received March 30, 2006; revision received April 26, 2006; accepted April 28, 2006.
Background— Eisenmenger syndrome is characterized by the development of pulmonary arterial hypertension with consequent intracardiac right-to-left shunt and hypoxemia in patients with preexisting congenital heart disease. Because Eisenmenger syndrome is associated with increased endothelin expression, patients may benefit from endothelin receptor antagonism. Theoretically, interventions that have some effect on the systemic vascular bed could worsen the shunt and increase hypoxemia.
Methods and Results— The Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) was a 16-week, multicenter, randomized, double-blind, placebo-controlled study evaluating the effect of bosentan, a dual endothelin receptor antagonist, on systemic pulse oximetry (primary safety end point) and pulmonary vascular resistance (primary efficacy end point) in patients with World Health Organization functional class III Eisenmenger syndrome. Hemodynamics were assessed by right- and left-heart catheterization. Secondary end points included exercise capacity assessed by 6-minute walk distance, additional hemodynamic parameters, functional capacity, and safety. Fifty-four patients were randomized 2:1 to bosentan (n=37) or placebo (n=17) for 16 weeks. The placebo-corrected effect on systemic pulse oximetry was 1.0% (95% confidence interval, –0.7 to 2.8), demonstrating that bosentan did not worsen oxygen saturation. Compared with placebo, bosentan reduced pulmonary vascular resistance index (–472.0 dyne · s · cm–5; P=0.0383). The mean pulmonary arterial pressure decreased (–5.5 mm Hg; P=0.0363), and the exercise capacity increased (53.1 m; P=0.0079). Four patients discontinued as a result of adverse events, 2 (5%) in the bosentan group and 2 (12%) in the placebo group.
Conclusions— In this first placebo-controlled trial in patients with Eisenmenger syndrome, bosentan was well tolerated and improved exercise capacity and hemodynamics without compromising peripheral oxygen saturation.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  A. M. Keogh, E. Mayer, R. L. Benza, P. Corris, P. G. Dartevelle, A. E. Frost, N. H. Kim, I. M. Lang, J. Pepke-Zaba, and J. Sandoval Interventional and surgical modalities of treatment in pulmonary hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S67 - S77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Barst, J. S. R. Gibbs, H. A. Ghofrani, M. M. Hoeper, V. V. McLaughlin, L. J. Rubin, O. Sitbon, V. F. Tapson, and N. Galie Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S78 - S84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin, D. B. Badesch, M. Delcroix, T. R. Fleming, S. P. Gaine, N. Galie, J. S. R. Gibbs, N. H. Kim, R. J. Oudiz, A. Peacock, et al. End Points and Clinical Trial Design in pulmonary arterial hypertension. J. Am. Coll. Cardiol., June 30, 2009; 54(1 Suppl): S97 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G.J. Duffels, M. Hardziyenka, S. Surie, R. H.A.C.M de Bruin-Bon, E. S. Hoendermis, A. P.J. van Dijk, B. J. Bouma, H. L. Tan, R. M.F. Berger, P. Bresser, et al. Duration of right ventricular contraction predicts the efficacy of bosentan treatment in patients with pulmonary hypertension Eur J Echocardiogr, May 1, 2009; 10(3): 433 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, R. S. Rosenson, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association Developed in Collaboration With the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1573 - 1619. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, V. V. McLaughlin, S. L. Archer, D. B. Badesch, R. J. Barst, H. W. Farber, J. R. Lindner, M. A. Mathier, M. D. McGoon, M. H. Park, et al. ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association Circulation, April 28, 2009; 119(16): 2250 - 2294. [Full Text] [PDF]
|
|
|
|
|
|
M. Beghetti and N. Galie Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension. J. Am. Coll. Cardiol., March 3, 2009; 53(9): 733 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galie, A. Manes, L. Negro, M. Palazzini, M. L. Bacchi-Reggiani, and A. Branzi A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur. Heart J., February 2, 2009; 30(4): 394 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bedard, K. Dimopoulos, and M. A. Gatzoulis Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension? Eur. Heart J., February 1, 2009; 30(3): 256 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S G Haworth and A A Hislop Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006 Heart, February 1, 2009; 95(4): 312 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease) Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons J. Am. Coll. Cardiol., December 2, 2008; 52(23): e143 - e263. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Warnes, R. G. Williams, T. M. Bashore, J. S. Child, H. M. Connolly, J. A. Dearani, P. del Nido, J. W. Fasules, T. P. Graham Jr, Z. M. Hijazi, et al. ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease): Developed in Collaboration With the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons Circulation, December 2, 2008; 118(23): e714 - e833. [Full Text] [PDF]
|
|
|
|
|
|
C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur. Heart J., June 17, 2008; (2008) ehn234v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Chin and L. J. Rubin Pulmonary arterial hypertension. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1527 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Bedard, D. F. Shore, and M. A. Gatzoulis Adult congenital heart disease: a 2008 overview Br. Med. Bull., March 1, 2008; 85(1): 151 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Dupuis and M. M. Hoeper Endothelin receptor antagonists in pulmonary arterial hypertension Eur. Respir. J., February 1, 2008; 31(2): 407 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.G. Coghlan and J. Davar How should we assess right ventricular function in 2008? Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H22 - H28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-P. Diller, K. Dimopoulos, H. Kafka, S. Y. Ho, and M. A. Gatzoulis Model of chronic adaptation: right ventricular function in Eisenmenger syndrome Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H54 - H60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Helman Jr, A. W. Brown, J. L. Jackson, and A. F. Shorr Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials Chest, September 1, 2007; 132(3): 764 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert Dual endothelin receptor antagonism: setting standards in PAH Eur. Respir. Rev., August 1, 2007; 16(102): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-P. Diller, K. Dimopoulos, M. G Kaya, C. Harries, A. Uebing, W. Li, E. Koltsida, J S. R Gibbs, and M. A Gatzoulis Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease Heart, August 1, 2007; 93(8): 974 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. McLaughlin Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines Chest, June 1, 2007; 131(6): 1917 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M D'Alto, C D Vizza, E Romeo, R Badagliacca, G Santoro, R Poscia, B Sarubbi, M Mancone, P Argiento, F Ferrante, et al. Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect Heart, May 1, 2007; 93(5): 621 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G.-P. Diller and M. A. Gatzoulis Pulmonary Vascular Disease in Adults With Congenital Heart Disease Circulation, February 27, 2007; 115(8): 1039 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mukhopadhyay, M. Sharma, S. Ramakrishnan, J. Yusuf, M. D. Gupta, N. Bhamri, V. Trehan, and S. Tyagi Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome: A Preliminary Observational Study Circulation, October 24, 2006; 114(17): 1807 - 1810. [Abstract] [Full Text] [PDF]
|
|